.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Dow
Covington
Boehringer Ingelheim
QuintilesIMS
US Army
Daiichi Sankyo
US Department of Justice
McKinsey
UBS

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,258,027

« Back to Dashboard

Summary for Patent: 4,258,027

Title: Multi-fractionable tablet structure
Abstract:The invention disclosed provides a multi-fractionable tablet structure initially configurated in a unitary dosage while having readily severable sub-dosage units as components thereof. Score markings are positioned variously about the tablet such as along the top and bottom surfaces thereof. Additionally, score markings may appear along opposite vertical side surfaces of the tablet. Special placement of the score markings readily permits alternatively an accurate equal bisectional or trisectional fracture of the tablet as may be desired for patient consumption.
Inventor(s): Ullman; Michael K. (Evansville, IN), David; Stephen T. (Evansville, IN), Gallian; Claude E. (Evansville, IN)
Assignee: Mead Johnson & Company (Evansville, IN)
Application Number:06/121,615
Patent Claim Types:
see list of patent claims
Dosage form;

No matches for this query

International Patent Family for Patent: 4,258,027

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria372853► Subscribe
AustriaA160880► Subscribe
Australia533115► Subscribe
Australia5647480► Subscribe
Belgium882426► Subscribe
Canada1133393► Subscribe
Switzerland644515► Subscribe
Cyprus1311► Subscribe
Germany3011680► Subscribe
Denmark128580► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Army
Federal Trade Commission
Accenture
Colorcon
Argus Health
UBS
Merck
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot